secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2022-09-23T23:59:59+00:00
Accession:  0001193125-22-249748
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Therapeutics prices $55M public offering of common stock and pre-funded warrants
--------------------------------------------------------------------------------

- Offering of 14,252,670 shares at $1.93/share and pre-funded warrants to buy 14,247,330 shares at $1.929 each.
- Gross proceeds ~$55M; net proceeds ~$51.4M (or ~$59.1M if underwriters' option exercised).
- Net proceeds to fund Haduvio clinical trials for chronic cough (IPF and refractory) into 2026.
- Company does not intend to use proceeds for prurigo nodularis program; Phase 2b IPF trial targeted for H1 2023.
- Closing expected September 27, 2022; SVB Securities, Stifel, and Oppenheimer as joint bookrunners.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000119312522249748/0001193125-22-249748-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000119312522249748/d378568d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-249748

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer